The New Mexico Cancer Center has begun offering Xofigo to its prostate cancer patients. Made by Bayer Healthcare, Xofigo, radium -223, has shown promise in recent studies for extending the survival rates of patients with advanced prostate cancer. Xofigo works by mimicking calcium within the body and binding to areas of rapid bone growth caused by bone tumors, thus limiting the damage caused by the tumors. Xofigo, once known as Alpharadin, received marketing approval from the FDA on May 15, 2013.
Check in with our UroSciences blog for the very latest news on prostate cancer, Peyronie’s disease, climacturia, and other urology topics. Learn more about our PDAD device for assessing Peyronie’s disease, and the UroStop for preventing urine leakage during sex.